Dr. Peter A. Merkel, MD, MPH
Rheumatology (Rheumatology Physician)
- Medicare participating
At a glance
- Medical school
- Yale University School of Medicine (1988)
- Years since graduation
- 38
- In the NPI registry since
- 2005
- Medicare patients seen, 2024
- 59
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1988Medical school: Yale University School of Medicine
- 2005Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Rheumatology Physician primary
PA license MD043272L · MA license 75719 -
Internal Medicine Physician
MA license 75719
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Hospital of Univ of Pennsylvania Philadelphia, PA
- Penn Presbyterian Medical Center Philadelphia, PA
Medical groups
- University of Penn - Medical Group (3,505 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 59
- Services billed
- 163
- Patients’ average age
- 72
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 30-39 minutes | 35 | 26 |
| Established patient office or other outpatient visit, 40-54 minutes | 20 | 18 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Payments from drug and device companies
In 2025, 13 companies reported 36 payments worth $71,402 in total to this clinician.
| Ns Pharma, Inc. | $31,488 |
|---|---|
| Alexion Pharmaceuticals, Inc. | $16,875 |
| Amgen Inc. | $6,914 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $5,189 |
| Argenx US, Inc. | $3,500 |
| AbbVie Inc. | $2,100 |
| AstraZeneca Pharmaceuticals LP | $1,950 |
| AstraZeneca UK Limited | $1,300 |
| Consulting Fee | $70,920 |
|---|---|
| Food and Beverage | $427 |
| Education | $54.99 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Ns Pharma, Inc. Jun 26, 2025 | Consulting Fee | $12,675 |
| Ns Pharma, Inc. Oct 30, 2025 | Consulting Fee | $8,400 |
| Ns Pharma, Inc. Jan 10, 2025 | Consulting Fee | $6,563 |
| Alexion Pharmaceuticals, Inc. Nov 26, 2025 | Consulting Fee | $3,900 |
| Ns Pharma, Inc. Jul 31, 2025 | Consulting Fee | $3,850 |
| Amgen Inc. Dec 17, 2025 | Consulting Fee BLINCYTO · Oncology | $3,500 |
| Alexion Pharmaceuticals, Inc. Oct 31, 2025 | Consulting Fee | $3,250 |
| Alexion Pharmaceuticals, Inc. Nov 12, 2025 | Consulting Fee | $3,250 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Sep 2, 2025 | Consulting Fee | $2,800 |
| Argenx US, Inc. Feb 5, 2025 | Consulting Fee | $2,800 |
All 26 payments other than meals, newest first
| Company | What it was for | Amount |
|---|---|---|
| Eli Lilly and Company Dec 18, 2025 | Consulting FeeCompany’s descriptionSERVICES TO SUPPORT RESEARCH RELATED ACTIVITIES | $1,200 |
| Amgen Inc. Dec 17, 2025 | Consulting Fee BLINCYTO · Oncology | $3,500 |
| Alexion Pharmaceuticals, Inc. Nov 26, 2025 | Consulting Fee | $3,900 |
| Alexion Pharmaceuticals, Inc. Nov 12, 2025 | Consulting Fee | $3,250 |
| Amgen Inc. Nov 7, 2025 | Consulting Fee TAVNEOS · Inflammation | $1,225 |
| Alexion Pharmaceuticals, Inc. Oct 31, 2025 | Consulting Fee | $3,250 |
| Ns Pharma, Inc. Oct 30, 2025 | Consulting Fee | $8,400 |
| Janssen Biotech, Inc. Oct 27, 2025 | Education TREMFYA · Immunology · in-kind | $54.99 |
| Alexion Pharmaceuticals, Inc. Sep 15, 2025 | Consulting Fee | $1,463 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Sep 2, 2025 | Consulting Fee | $2,800 |
| Amgen Inc. Aug 11, 2025 | Consulting Fee TAVNEOS · Inflammation | $1,050 |
| Amgen Inc. Aug 7, 2025 | Consulting Fee TAVNEOS · Inflammation | $1,050 |
| Ns Pharma, Inc. Jul 31, 2025 | Consulting Fee | $3,850 |
| AbbVie Inc. Jul 25, 2025 | Consulting Fee | $2,100 |
| Alexion Pharmaceuticals, Inc. Jul 14, 2025 | Consulting Fee | $650 |
| Alexion Pharmaceuticals, Inc. Jul 9, 2025 | Consulting Fee | $1,625 |
| Ns Pharma, Inc. Jun 26, 2025 | Consulting Fee | $12,675 |
| Alexion Pharmaceuticals, Inc. Jun 26, 2025 | Consulting Fee | $650 |
| Alexion Pharmaceuticals, Inc. Apr 16, 2025 | Consulting Fee | $1,950 |
| AstraZeneca Pharmaceuticals LP Feb 24, 2025 | Consulting Fee FASENRA · Respiratory | $1,950 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Feb 14, 2025 | Consulting Fee | $2,320 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. Feb 6, 2025 | Consulting Fee | $700 |
| Argenx US, Inc. Feb 5, 2025 | Consulting Fee | $2,800 |
| Argenx US, Inc. Feb 5, 2025 | Consulting Fee | $700 |
| Ns Pharma, Inc. Jan 10, 2025 | Consulting Fee | $6,563 |
| AstraZeneca UK Limited Jan 6, 2025 | Consulting Fee | $1,300 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 7 industry-funded studies in 2025, from 5 companies. The companies reported $544,931 in research payments for these studies, mostly to the institutions running them.
- Vasculitis Clinical Research Consortium Eosinophilic Granulomatosis with Polyangiitis Registry
AstraZeneca Pharmaceuticals LP - A Randomized Double-Blind, Placebo Controlled Trial of Abatacept (CTLA4-Ig) in Giant Cell Arteritis (ABAGART)
E.r. Squibb & Sons, L.l.c. - A Randomized, Double-Blind, Active-Controlled, Phase 3 Study to Evaluate the Safety and Efficacy of CCX168 (Avacopan) in Patients With ANCA-Associated Vasculitis Treated Concomitantly With Rituximab or Cyclophosphamid…
Amgen Inc. - A Randomised, Double-blind, Active-controlled 52-week Study with an Open-label Extension to Evaluate the Efficacy and Safety of Benralizumab Compared to Mepolizumab in the Treatment of Eosinophilic Granulomatosis with…
AstraZeneca Pharmaceuticals LP - A Study to Evaluate the Safety and Efficacy of Upadacitinib in Participants With Giant Cell Arteritis
AbbVie Inc. · Completed · NCT03725202 - M16-852 - A Study to Evaluate the Safety and Efficacy of Upadacitinib in Participants With Giant Cell Arteritis
AbbVie Inc. - A 52-week, randomized, double-blind, double-dummy, parallel-group, mul
GlaxoSmithKline, LLC.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.